OTCMKTS:INCPF InnoCare Pharma 10/27/2026 Earnings Report $1.85 0.00 (0.00%) As of 10/2/2026 ProfileForecast InnoCare Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/AInnoCare Pharma Revenue ResultsActual RevenueN/AExpected Revenue$22.99 millionBeat/MissN/AYoY Revenue GrowthN/AInnoCare Pharma Announcement DetailsQuarterDate10/27/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile InnoCare Pharma Earnings HeadlinesChina's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billionSeptember 23, 2026 | reuters.comInnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call TranscriptAugust 24, 2026 | seekingalpha.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)InnoCare Pharma Sets Board Meeting to Approve 2026 Interim ResultsAugust 11, 2026 | tipranks.comChina's Innocare's psoriasis drug meets main goal in late-stage trialJuly 27, 2026 | reuters.comInnoCare Shareholders Approve All Resolutions at 2026 AGMJune 16, 2026 | tipranks.comSee More InnoCare Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InnoCare Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InnoCare Pharma and other key companies, straight to your email. Email Address About InnoCare PharmaInnoCare Pharma (OTCMKTS:INCPF) is a China-based biopharmaceutical company focused on discovering, developing and commercializing therapies for cancer and autoimmune diseases. The company uses small-molecule and biologic drug development technologies to target diseases with significant unmet medical needs. Its principal commercial product is orelabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of certain B-cell malignancies. Orelabrutinib has received approval in China for indications including relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma. InnoCare also has a pipeline of investigational therapies addressing hematologic cancers, solid tumors and autoimmune conditions. Founded in 2015, InnoCare conducts research and development activities in China and has expanded its international presence through collaborations and development efforts in overseas markets. The company is led by co-founder and Chief Executive Officer Dr. Jasmine Cui, who has a background in pharmaceutical research and drug development.View InnoCare Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
